Status In progress
Decision Selected
Process STA Review
ID number 3778

Provisional Schedule

Expected publication 08 June 2022

Project Team

Project lead Thomas Feist

Email enquiries

External Assessment Group School of Health and Related Research (ScHARR), University of Sheffield

Stakeholders

Companies sponsors Janssen
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Lymphoma Action
  WMUK
Professional groups Association of Cancer Physicians
  British Society for Haematology
  Cancer Research UK
  Royal College of Pathologists
  Royal College of Physicians
Comparator companies Janssen-Cilag
General commentators All Wales Therapeutic Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee

Timeline

Key events during the development of the guidance:

Date Update
06 May 2022 - 19 May 2022 Final draft guidance
21 January 2022 - 11 February 2022 Draft guidance
07 December 2021 Committee meeting: 1
10 June 2021 Invitation to participate
19 March 2021 In progress. Topic is in progress

For further information on our processes and methods, please see our CHTE processes and methods manual